Dhanya B. Sen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dhanya B. Sen has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara-391760, Gujarat, India
13 shared publications - Rajesh A. Maheshwari
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
7 shared publications Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India
6 shared publications- Ramachandran Balaraman
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara – 391760, Gujarat
6 shared publications Aarti S. Zanwar
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India
5 shared publicationsRajesh A. Maheshwari
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India
5 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1473-1506
Ethnobotanical Perspective and Pharmacological Insights of North East Indian Medicinal Plants Ameliorating Diabetic Wound: A Comprehensive Review
The escalating global health crisis of diabetes mellitus, projected to affect 783 million individuals by 2045, is frequently complicated by impaired wound healing, imposing substantial economic burdens. This study addresses the critical need for innovative therapeutic interventions by investigating the potential of the North East Indian flora to mitigate the chronicity of diabetic wounds. By integrating ethnobotanical knowledge with rigorous scientific inquiry, we aim to identify and validate indigenous herbs that possess significant wound-healing properties relevant to the diabetic milieu. Our review focuses on elucidating the phytoconstituent profiles and pharmacological mechanisms of selected herbs, specifically targeting pathways involved in impaired angiogenesis, inflammation dysregulation, and compromised tissue regeneration characteristic of diabetic wounds. This review employed a comprehensive literature search across PubMed, Google Scholar, and ScienceDirect databases. Keywords included “Northeast India plants”, “diabetic wound”, and “phytoconstituents for wound healing”. This study summarised 26 bioactive phytochemicals and 24 medicinal plants that have been shown to impact diabetic wound healing. The outcomes of this investigation hold promise for developing evidence-based herbal formulations, offering accessible and culturally congruent therapeutic strategies to enhance diabetic wound repair and alleviate the associated healthcare burden. Major Findings: This review explores traditional Northeast Indian herbs that enhance angiogenesis, reduce inflammation, and promote tissue regeneration. Numerous plants exhibit potent antioxidant, anti-inflammatory, antimicrobial, and pro-angiogenic properties. The identified phytochemicals and medicinal plants have considerable potential to inform culturally relevant, evidence-based strategies for managing diabetic wounds.
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1473-1506
Open AccessEthnobotanical Perspective and Pharmacological Insights of North East Indian Medicinal Plants Ameliorating Diabetic Wound: A Comprehensive Review
The escalating global health crisis of diabetes mellitus, projected to affect 783 million individuals by 2045, is frequently complicated by impaired wound healing, imposing substantial economic burdens. This study addresses the critical need for innovative therapeutic interventions by investigating the potential of the North East Indian flora to mitigate the chronicity of diabetic wounds. By integrating ethnobotanical knowledge with rigorous scientific inquiry, we aim to identify and validate indigenous herbs that possess significant wound-healing properties relevant to the diabetic milieu. Our review focuses on elucidating the phytoconstituent profiles and pharmacological mechanisms of selected herbs, specifically targeting pathways involved in impaired angiogenesis, inflammation dysregulation, and compromised tissue regeneration characteristic of diabetic wounds. This review employed a comprehensive literature search across PubMed, Google Scholar, and ScienceDirect databases. Keywords included “Northeast India plants”, “diabetic wound”, and “phytoconstituents for wound healing”. This study summarised 26 bioactive phytochemicals and 24 medicinal plants that have been shown to impact diabetic wound healing. The outcomes of this investigation hold promise for developing evidence-based herbal formulations, offering accessible and culturally congruent therapeutic strategies to enhance diabetic wound repair and alleviate the associated healthcare burden. Major Findings: This review explores traditional Northeast Indian herbs that enhance angiogenesis, reduce inflammation, and promote tissue regeneration. Numerous plants exhibit potent antioxidant, anti-inflammatory, antimicrobial, and pro-angiogenic properties. The identified phytochemicals and medicinal plants have considerable potential to inform culturally relevant, evidence-based strategies for managing diabetic wounds.
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- 1 October 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (10) , 4695-4703
A Robust High-performance Thin-layer Chromatographic Method for the precise quantification of Lobeglitazone sulfate in Tablet Formulation
A tablet with a fixed dose of 0.5 mg lobeglitazone sulfate has been proven to effectively improve glycemic management in individuals with diabetes mellitus. The objective of this study was to develop and validate an efficient thin-layer chromatographic method for accurately measuring the amount of lobeglitazone sulfate in tablet form. The objective is to develop and validate a method, following the ICH recommendations, for precise quantification of lobeglitazone sulfate in tablet formulation. The analysis employed aluminium plates coated with silica gel 60F254 for high-performance thin-layer chromatography. The solvent system used was a mixture of toluene: ammonium acetate: acetonitrile and triethyl amine in a ratio of 4:2.5:1.5:0.2 v/v/v/v. The resulting chromatogram was then scanned at a wavelength of 248 nm using densitometry. The approach demonstrated a linear relationship in the range of 100-1500 ng/band for lobeglitazone sulfate, with correlation coefficient of 0.9991. Remarkable sensitivity was noted, with detection limits of 17.31 ng/band and quantification limits of 52.46 ng/band for lobeglitazone sulfate. The approach exhibited high precision, with a relative standard deviation of peak area below 2%. Additionally, it demonstrated accuracy, with a recovery rate ranging between 98% and 101%. The proposed methodology is suitable for measuring the specified drug in tablet formulations, making it useful for regular quality control evaluations in laboratories.
- 1 October 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (10) , 4695-4703
A Robust High-performance Thin-layer Chromatographic Method for the precise quantification of Lobeglitazone sulfate in Tablet Formulation
A tablet with a fixed dose of 0.5 mg lobeglitazone sulfate has been proven to effectively improve glycemic management in individuals with diabetes mellitus. The objective of this study was to develop and validate an efficient thin-layer chromatographic method for accurately measuring the amount of lobeglitazone sulfate in tablet form. The objective is to develop and validate a method, following the ICH recommendations, for precise quantification of lobeglitazone sulfate in tablet formulation. The analysis employed aluminium plates coated with silica gel 60F254 for high-performance thin-layer chromatography. The solvent system used was a mixture of toluene: ammonium acetate: acetonitrile and triethyl amine in a ratio of 4:2.5:1.5:0.2 v/v/v/v. The resulting chromatogram was then scanned at a wavelength of 248 nm using densitometry. The approach demonstrated a linear relationship in the range of 100-1500 ng/band for lobeglitazone sulfate, with correlation coefficient of 0.9991. Remarkable sensitivity was noted, with detection limits of 17.31 ng/band and quantification limits of 52.46 ng/band for lobeglitazone sulfate. The approach exhibited high precision, with a relative standard deviation of peak area below 2%. Additionally, it demonstrated accuracy, with a recovery rate ranging between 98% and 101%. The proposed methodology is suitable for measuring the specified drug in tablet formulations, making it useful for regular quality control evaluations in laboratories.
- Open Access
- 25 June 2025
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 17 (3) , 728-739
Extraction and Quantification of Allicin: A Bioactive Component of Allium sativum
Allicin, a bioactive compound found in garlic, exhibits remarkable pharmacological properties such as antimicrobial, antioxidant, and anticancer effects. Its therapeutic potential has garnered substantial attention, leading to efforts to refine extraction and quantification methods for precise analysis in garlic-based products. This review examines advanced techniques for allicin extraction from garlic, including Ultrasonic-Assisted Extraction (UAE), Supercritical Water Extraction (SCWE), and Microwave-Assisted Extraction (MAE). UAE employs ultrasonic waves to improve mass transfer and solvent penetration, optimizing allicin yield while reducing extraction time. SCWE utilizes the unique properties of water above its critical point to extract allicin efficiently and selectively, providing an eco-friendly alternative. MAE uses microwave energy to rapidly heat solvents, enhancing allicin extraction through improved penetration and dissolution. Alongside these extraction methods, this review highlights analytical techniques for allicin quantification, including High-Performance Liquid Chromatography (HPLC), High-Performance Thin-Layer Chromatography (HPTLC), and Ultraviolet (UV) spectroscopy. HPLC offers exceptional sensitivity and specificity for splitting and measuring allicin in complex matrices, making it invaluable for accurate pharmacokinetic studies and quality control of pharmaceutical formulations. HPTLC offers quick screening with minimal sample preparation, ideal for routine investigation and batch testing of garlic extracts. UV spectroscopy, a cost-effective technique, detects allicin through its characteristic absorption spectra, enabling quick evaluations of garlic product quality and stability. This review consolidates recent advancements in allicin extraction and quantification techniques, emphasizing their applications in the pharmaceutical, nutraceutical, and food sectors. Future research aims to optimize extraction parameters to maximize allicin yield and develop robust analytical methods to address the growing demand for quality assurance and therapeutic efficacy in garlic-based products.
- 25 June 2025
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 17 (3) , 728-739
Open AccessExtraction and Quantification of Allicin: A Bioactive Component of Allium sativum
Allicin, a bioactive compound found in garlic, exhibits remarkable pharmacological properties such as antimicrobial, antioxidant, and anticancer effects. Its therapeutic potential has garnered substantial attention, leading to efforts to refine extraction and quantification methods for precise analysis in garlic-based products. This review examines advanced techniques for allicin extraction from garlic, including Ultrasonic-Assisted Extraction (UAE), Supercritical Water Extraction (SCWE), and Microwave-Assisted Extraction (MAE). UAE employs ultrasonic waves to improve mass transfer and solvent penetration, optimizing allicin yield while reducing extraction time. SCWE utilizes the unique properties of water above its critical point to extract allicin efficiently and selectively, providing an eco-friendly alternative. MAE uses microwave energy to rapidly heat solvents, enhancing allicin extraction through improved penetration and dissolution. Alongside these extraction methods, this review highlights analytical techniques for allicin quantification, including High-Performance Liquid Chromatography (HPLC), High-Performance Thin-Layer Chromatography (HPTLC), and Ultraviolet (UV) spectroscopy. HPLC offers exceptional sensitivity and specificity for splitting and measuring allicin in complex matrices, making it invaluable for accurate pharmacokinetic studies and quality control of pharmaceutical formulations. HPTLC offers quick screening with minimal sample preparation, ideal for routine investigation and batch testing of garlic extracts. UV spectroscopy, a cost-effective technique, detects allicin through its characteristic absorption spectra, enabling quick evaluations of garlic product quality and stability. This review consolidates recent advancements in allicin extraction and quantification techniques, emphasizing their applications in the pharmaceutical, nutraceutical, and food sectors. Future research aims to optimize extraction parameters to maximize allicin yield and develop robust analytical methods to address the growing demand for quality assurance and therapeutic efficacy in garlic-based products.
- Open Access
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Exploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Open AccessExploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- 21 February 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (2)
A Stability Indicating HPLC Methodology Applying Quality by Design for the Concurrent Estimation of Luliconazole and Clobetasol Propionate in Cream Formulation
Antifungal agents containing azole ring (luliconazole [LULI]) and corticosteroid (clobetasol propionate [CLOB]) combination shows great therapeutic effects on skin infections by eliminating the fungus that is responsible for the infection and reducing the inflammation of the skin. The research work intended to create a liquid chromatographic methodology with stability study for estimating LULI and CLOB applying design of experiment approach. LULI and CLOB were analyzed utilizing a Hypersil BDS C 18 column (250 × 4.6 mm, 5 µm), using elution solvent comprising 0.1 M sodium phosphate buffer (pH 6.0) combined with methanol in a ratio of 40:60 v/v. The proposed method a flow rate of 1 mL/min and a detection wavelength of 240 nm. A 3 2 full factorial design was utilized to optimize the mobile phase. The methodology had undergone validation using ICH strategies. The study on force degradation was conducted for the cream formulation containing both the drugs. The satisfactory linearity range for LULI was found to be 10–30 µg/mL, whereas 0.5–1.5 µg/mL for CLOB. The method demonstrated good sensitivity, with detection limit and quantification limit of 0.255 and 0.774 µg/mL for LULI along with 0.106 and 0.322 µg/mL for CLOB. The established methodology was found to be precise (%RSD < 2) and accurate (recovery between 98% and 102%). The degradation studies aimed to confirm the efficient separation of LULI and CLOB from their degradation products. From the degradation chromatograms it has been demonstrated that any degradation products, if present, do not interfere with the active constituents.
- 21 February 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (2)
A Stability Indicating HPLC Methodology Applying Quality by Design for the Concurrent Estimation of Luliconazole and Clobetasol Propionate in Cream Formulation
Antifungal agents containing azole ring (luliconazole [LULI]) and corticosteroid (clobetasol propionate [CLOB]) combination shows great therapeutic effects on skin infections by eliminating the fungus that is responsible for the infection and reducing the inflammation of the skin. The research work intended to create a liquid chromatographic methodology with stability study for estimating LULI and CLOB applying design of experiment approach. LULI and CLOB were analyzed utilizing a Hypersil BDS C 18 column (250 × 4.6 mm, 5 µm), using elution solvent comprising 0.1 M sodium phosphate buffer (pH 6.0) combined with methanol in a ratio of 40:60 v/v. The proposed method a flow rate of 1 mL/min and a detection wavelength of 240 nm. A 3 2 full factorial design was utilized to optimize the mobile phase. The methodology had undergone validation using ICH strategies. The study on force degradation was conducted for the cream formulation containing both the drugs. The satisfactory linearity range for LULI was found to be 10–30 µg/mL, whereas 0.5–1.5 µg/mL for CLOB. The method demonstrated good sensitivity, with detection limit and quantification limit of 0.255 and 0.774 µg/mL for LULI along with 0.106 and 0.322 µg/mL for CLOB. The established methodology was found to be precise (%RSD < 2) and accurate (recovery between 98% and 102%). The degradation studies aimed to confirm the efficient separation of LULI and CLOB from their degradation products. From the degradation chromatograms it has been demonstrated that any degradation products, if present, do not interfere with the active constituents.
- 23 January 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Concurrent Analysis of Racecadotril, Ofloxacin, and Ornidazole in a Fixed‐Dose Combination by RP‐HPLC–DAD Method
The pharmaceutical combination of Racecadotril (RAC), Ofloxacin (OFL), and Ornidazole (ORN) is a commonly prescribed treatment for diarrhea and dysentery in pediatric patients. A rapid and highly sensitive reverse phase–high‐performance liquid chromatography–diode array detector (RP‐HPLC–DAD) method has been established for the concurrent analysis of all three drugs in a combined oral suspension. Drugs were separated by chromatography using a Sapphire octadecylsilane (ODS) C18 (150 × 4.6 mm, 5 µm) column, operated at 30°C. The elution solvent consisted of a mixture of acetonitrile and 0.1% triethylamine solution (70:30 v/v), with the pH adjusted to 3.1 using 10% orthophosphoric acid. The flow rate was maintained at 1 mL/min, and all three drugs were monitored at 230 nm. The method showed linearity within the ranges: RAC (3–9 µg/mL), OFL (10–30 µg/mL), and ORN (25–75 µg/mL). Retention times were 2.03 min for OFL, 2.99 min for ORN, and 6.99 min for RAC. The drug content for RAC, OFL, and ORN ranged from 100.92% to 101.39%, 98.55% to 100.76%, and 99.33% to 101.22%, respectively, with recoveries of 96.33%–102.16%, 97.50%–101.32%, and 98.25%–100.76%, and %RSD values consistently below 2 in within‐day, between‐day, and repeatability studies, demonstrating method precision. The projected chromatography technique has been authenticated in line with International Council on Harmonization Q2 (R1) guidelines. This approach offers a short runtime of 10 min, providing an economically efficient chromatographic technique for the concomitant assessment of RAC, OFL, and ORN in a combined oral suspension preparation.
- 23 January 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (1)
Concurrent Analysis of Racecadotril, Ofloxacin, and Ornidazole in a Fixed‐Dose Combination by RP‐HPLC–DAD Method
The pharmaceutical combination of Racecadotril (RAC), Ofloxacin (OFL), and Ornidazole (ORN) is a commonly prescribed treatment for diarrhea and dysentery in pediatric patients. A rapid and highly sensitive reverse phase–high‐performance liquid chromatography–diode array detector (RP‐HPLC–DAD) method has been established for the concurrent analysis of all three drugs in a combined oral suspension. Drugs were separated by chromatography using a Sapphire octadecylsilane (ODS) C18 (150 × 4.6 mm, 5 µm) column, operated at 30°C. The elution solvent consisted of a mixture of acetonitrile and 0.1% triethylamine solution (70:30 v/v), with the pH adjusted to 3.1 using 10% orthophosphoric acid. The flow rate was maintained at 1 mL/min, and all three drugs were monitored at 230 nm. The method showed linearity within the ranges: RAC (3–9 µg/mL), OFL (10–30 µg/mL), and ORN (25–75 µg/mL). Retention times were 2.03 min for OFL, 2.99 min for ORN, and 6.99 min for RAC. The drug content for RAC, OFL, and ORN ranged from 100.92% to 101.39%, 98.55% to 100.76%, and 99.33% to 101.22%, respectively, with recoveries of 96.33%–102.16%, 97.50%–101.32%, and 98.25%–100.76%, and %RSD values consistently below 2 in within‐day, between‐day, and repeatability studies, demonstrating method precision. The projected chromatography technique has been authenticated in line with International Council on Harmonization Q2 (R1) guidelines. This approach offers a short runtime of 10 min, providing an economically efficient chromatographic technique for the concomitant assessment of RAC, OFL, and ORN in a combined oral suspension preparation.
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- 10 May 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (7)
Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
A combination of fixed dose tablet containing 0.5 mg lobeglitazone sulfate (LBZ) and 1 mg glimepiride (GLM) has demonstrated efficacy in enhancing glycemic control in diabetes. The projected work aimed to develop and validate a high‐performance thin‐layer chromatographic (HPTLC) methodology for the precise quantification of both the drugs in tablet formulations. The HPTLC analysis utilized aluminium plates layered with silica gel 60F 254 , and the solvent system consisted of ethyl acetate, benzene, and hexane (4:3:1 v/v/v) followed by densitometric scanning at 238 nm. The R f value was found to be 0.68 ± 0.001 for LBZ and 0.48 ± 0.002 for GLM. The methodology exhibited linearity in the range of 100–2000 ng/band for LBZ and 200–4000 ng/band for GLM, with correlation coefficients of 0.9988 and 0.9981, respectively. Exceptional sensitivity was observed, with detection limits of 23.86 ng/band for LBZ and 58.26 ng/band for GLM, along with quantification limits of 72.32 ng/band for LBZ and 176.55 ng/band for GLM. The method demonstrated precision (% relative standard deviation of peak area < 2) and accuracy (recovery between 97% and 102%). The suggested method is suitable for quantifying both the drugs in tablets, making it useful for routine quality control in laboratories.
- 10 May 2024
- Published by Wiley in Separation Science Plus
- Vol. 7 (7)
Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
A combination of fixed dose tablet containing 0.5 mg lobeglitazone sulfate (LBZ) and 1 mg glimepiride (GLM) has demonstrated efficacy in enhancing glycemic control in diabetes. The projected work aimed to develop and validate a high‐performance thin‐layer chromatographic (HPTLC) methodology for the precise quantification of both the drugs in tablet formulations. The HPTLC analysis utilized aluminium plates layered with silica gel 60F 254 , and the solvent system consisted of ethyl acetate, benzene, and hexane (4:3:1 v/v/v) followed by densitometric scanning at 238 nm. The R f value was found to be 0.68 ± 0.001 for LBZ and 0.48 ± 0.002 for GLM. The methodology exhibited linearity in the range of 100–2000 ng/band for LBZ and 200–4000 ng/band for GLM, with correlation coefficients of 0.9988 and 0.9981, respectively. Exceptional sensitivity was observed, with detection limits of 23.86 ng/band for LBZ and 58.26 ng/band for GLM, along with quantification limits of 72.32 ng/band for LBZ and 176.55 ng/band for GLM. The method demonstrated precision (% relative standard deviation of peak area < 2) and accuracy (recovery between 97% and 102%). The suggested method is suitable for quantifying both the drugs in tablets, making it useful for routine quality control in laboratories.
- 9 November 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (1)
Densitometric simultaneous assessment of teneligliptin hydrobromide and pioglitazone hydrochloride in combined tablet
A highly effective high‐performance thin‐layer chromatographic methodology has been developed and validated for the concurrent measurement of teneligliptin hydrobromide hydrate and pioglitazone hydrochloride in tablet offering excellent sensitivity, precision, accuracy, and robustness. The methodology involved using aluminum plates layered with silica gel 60F 254 were used, and the solvent system consisted of a mixture of chloroform, methanol, and ammonia (8:1:0.5 v/v/v). The analysis involved scanning of the plate at a wavelength of 229 nm and analyzing the resulting densitograms. The linear correlation was established over a range of concentrations 250–3000 ng/band for teneligliptin hydrobromide hydrate and 187.5–2250 ng/band for pioglitazone hydrochloride. The method displayed detection limits of 21.29 ng/band for teneligliptin hydrobromide hydrate and 25.97 ng/band for pioglitazone hydrochloride. The quantification limits were 64.52 ng/band for teneligliptin hydrobromide hydrate and 78.71 ng/band for pioglitazone hydrochloride. The results of precision parameters showed that the % relative standard deviation of peak area was consistently below 2%, indicating high precision. The accuracy of the method was demonstrated to be between 96% and 103%. Proposed method was found to be superior and capable of overcoming the shortcomings of previously reported methods for the assessment of both the drugs.
- 9 November 2023
- Published by Wiley in Separation Science Plus
- Vol. 7 (1)
Densitometric simultaneous assessment of teneligliptin hydrobromide and pioglitazone hydrochloride in combined tablet
A highly effective high‐performance thin‐layer chromatographic methodology has been developed and validated for the concurrent measurement of teneligliptin hydrobromide hydrate and pioglitazone hydrochloride in tablet offering excellent sensitivity, precision, accuracy, and robustness. The methodology involved using aluminum plates layered with silica gel 60F 254 were used, and the solvent system consisted of a mixture of chloroform, methanol, and ammonia (8:1:0.5 v/v/v). The analysis involved scanning of the plate at a wavelength of 229 nm and analyzing the resulting densitograms. The linear correlation was established over a range of concentrations 250–3000 ng/band for teneligliptin hydrobromide hydrate and 187.5–2250 ng/band for pioglitazone hydrochloride. The method displayed detection limits of 21.29 ng/band for teneligliptin hydrobromide hydrate and 25.97 ng/band for pioglitazone hydrochloride. The quantification limits were 64.52 ng/band for teneligliptin hydrobromide hydrate and 78.71 ng/band for pioglitazone hydrochloride. The results of precision parameters showed that the % relative standard deviation of peak area was consistently below 2%, indicating high precision. The accuracy of the method was demonstrated to be between 96% and 103%. Proposed method was found to be superior and capable of overcoming the shortcomings of previously reported methods for the assessment of both the drugs.